CLARIS-INTERNATIONAL
28.10.2020 07:02:12 CET | Business Wire | Press release
Claris International Inc., an Apple subsidiary and pioneering leader in low-code, today announced the official launch of FileMaker Cloud to EMEA markets. FileMaker Cloud gives EMEA businesses all of the power of the cloud - sharing, rapid deployment, scalability - without compromising on performance or losing connection to the real world of devices, sensors, even offline apps. The result is a future-proof solution that empowers businesses to rapidly create and share intelligent apps with their teams, and integrate them with other popular apps and web services.
“For so many businesses, the global pandemic changed every aspect of their business overnight, which led to a massive boom in both low-code adoption and remote work technologies,” said Brad Freitag, CEO of Claris. “In many ways, Claris was built for this moment. Our commitment to low-code without limits - quickly deploying intelligent apps that both solve and evolve - means the solutions our customers build to deal with today’s changes can serve as their IT backbone going forward. We’re thrilled to finally bring FileMaker Cloud to EMEA as we continue to power the workplace of tomorrow through limitless and scalable low-code solutions.”
Designed to augment its widely adopted Claris Platform, FileMaker Cloud offers localised infrastructure to assist businesses with implementing General Data Protection Regulation (GDPR) and German Bundesdatenschutzgesetz (BDSG) compliance, while also providing a scalable, agile, and adaptable solution to drive IT impact in EMEA. The FileMaker Cloud solution also brings emerging technologies within reach, ready to leverage artificial intelligence (AI), machine learning (ML), digital assistants, Internet of Things, augmented and virtual reality, and whatever comes next.
FileMaker Cloud offers the following capabilities:
- Agility and speed: Ability to rapidly deploy within an organisation without software or hardware. Start creating and sharing custom apps 4x faster.
- Streamlined management: Easily manage users and groups in one secure place, including full tracking, and visibility.
- Privacy, security and support: Provides end-to-end encryption, multi-factor authentication, and dedicated 24/7 support and monitoring by expert teams to ensure premium security and performance.
- Hassle-free infrastructure: Access to fully configured hardware and installed software, as well as automated server maintenance.
- Future-proof scalability: Ability to rapidly scale across departments and entire businesses for fast-paced growth.
- Affordable, set prices: Yearly subscription fee of €41 EUR per month, available for purchase in local currency.
- Certificates: Built-in SSL certificate included with the service.
- Local language support: Access to multiple languages, including French, Italian, German, and Spanish.
For more information or to purchase FileMaker Cloud, please visit store.filemaker.com .
About Claris International Inc.
Claris International Inc. is the creator of the world's leading rapid, low-code development platform, offering a suite of services that empower problem solvers to drive digital transformation in businesses large and small. The company has more than 1.3 million active users globally across SMBs and the Fortune 500. Claris is an Apple subsidiary with an unmatched record of business success of more than 80 consecutive profitable quarters. Claris is headquartered in California with operations worldwide, including London, Paris, Munich, Tokyo, Beijing, and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027006244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
